GRFS
Stock Details
GRFS is Grifols, S.A.'s stock. Stock exchange NasdaqGS (Currency USD). Average price in 50 days is 11.52$. Average daily volumn in 3 months 1.03M. Market cap 12.32B
Stock symbol : GRFS. Exchange : NasdaqGS. Currency : USD Lastest price : 13.07$. Total volume : 703.58k. Market state POST Click reload if you want to check the lastest price on market!!!
Grifols, S.A. (GRFS)
Last Price
13.07$Change
-0.21Volume
703.58k
| Previous Close | 13.28 |
| Open | 13.15 |
| Day Range | 12.88-13.20 |
| Bid | 12.60 x 1.8k |
| Ask | 14.50 x 1.8k |
| Volume | 703.58k |
| Average Volume | 1.03M |
| Market Cap | 12.32B |
| Beta | 0.17 |
| 52 Week Range | 10.10-19.07 |
| Trailing P/E | 91.40 |
| Foward P/E | 15.38 |
| Dividend (Yield %) | 6.88% |
| Ex-Dividend Date | 2021-06-03 |
Financial Details
Organization
Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products, primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others divisions. The Bioscience division researches, develops, produces, and markets plasma-derived medicines and other innovative solutions to treat patients with chronic, rare, prevalent, and life-threatening diseases. It offers immunoglobulins, alpha-1 antitrypsin, albumin, clotting fa... ctors, and hyperimmune globulins. The Hospital division offers non-biological pharmaceutical products and medical supplies clinical nutrition, intravenous therapy, and medical devices. The Diagnostic division researches, develops, produces, and commercializes diagnostic products that span the healthcare continuumยfrom prevention, screening, diagnosis, and prognosis to disease and treatment monitoringยto serve professionals. The Bio Supplies division provides biological materials for life-science research, clinical trials, and for manufacturing pharmaceutical and diagnostic products. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves public and private customers; and wholesalers, distributors, group purchasing organizations, blood banks, hospitals and care institutions, and national health systems. Grifols, S.A. has a technology collaboration agreement with Mondragon. The company was founded in 1940 and is headquartered in Barcelona, Spain.
Market Cap:
12.32BRevenue:
4.93BTotal Assets:
19.23BTotal Cash:
655.49M
News about "Grifols, S.A."
Grifols, S.A. (NASDAQ:GRFS) Receives Consensus Rating of โHoldโ from Analysts
Source from : ETF Daily News - 21 days ago
Shares of Grifols, S.A. (NASDAQ:GRFS โ Get Rating) have been given a consensus rating of โHoldโ by the nine brokerages that are currently covering the company, Marketbeat.com reports.See details»
Wall Street Pummels Grifols S.A. (GRFS) After Recent Earnings Report
Source from : newsheater - 6 days ago
Grifols S.A. (NASDAQ:GRFS) went up by 0.31% from its latest closing price compared to the recent 1-year high of $19.07. The companyโs stock price has collected 3.27% of gains in the last five trading ...See details»
Grifols, S.A.: Slightly Adjusting Grifols Fair Value Estimate on FX Fluctuations; Strong Q1, Shares Undervalued
Source from : Yahoo Finance - 16 days ago
As a vertically integrated plasma derivative producer, Spain-based Grifols collects plasma and then manufactures and sells plasma-derived products globally. By acquiring Talecris in 2011 ...See details»
Grifols (NASDAQ:GRFS) Downgraded to โSellโ at Zacks Investment Research
Source from : ETF Daily News - 22 days ago
According to Zacks, โGrifols, S.A., operates in the pharmaceutical-hospital sector engaged in the research, development and retailing of plasma derivates, products for intravenous therapy ...See details»
Grifols SA B - Stock Quote GRFPE
Source from : Morningstar%2c Inc. - 3 days ago
There is no one analyst in which a Quantitative Star Rating and Fair Value Estimate is attributed to; however, Mr. Lee Davidson, Head of Quantitative Research for Morningstar, Inc., is responsible ...See details»
Grifols SA ADR - Stock Quote GIKLY
Source from : Morningstar%2c Inc. - 6 days ago
There is no one analyst in which a Quantitative Star Rating and Fair Value Estimate is attributed to; however, Mr. Lee Davidson, Head of Quantitative Research for Morningstar, Inc., is responsible ...See details»
Grifols SA - ADR - Level III
Source from : U.S. News & World Report - 7 days ago
Investors seeking a good entry point have plenty of options among the best cryptocurrencies to buy now.See details»
Grifols: Long Only
Source from : Seeking Alpha - 15 days ago
After the results, we are more confident on Grifols' ability to navigate the short-term analyst downgrade. Biotest acquisition completed, now it is time to deliver. Given the strong company track ...See details»
Grifols completes the acquisition of Biotest: a strategic and transformational transaction to accelerate growth and innovation
Source from : Stockhouse - 1 month ago
Grifols, S.A. does not accept any obligation to publicly report, revise or update future projections or assumptions to adapt them to events or circumstances subsequent to the date of writing this ...See details»
Blood Transfusion Diagnostics Market is experiencing boost at an infinite speed By 2032 | Grifols S.A., Immucor Inc., Ortho Clinical Diagnostics
Source from : xaralite.com - 3 days ago
According to the report by insightSLICE, titled, โBlood Transfusion Diagnostics market: Global Market Share, Trends, Analysis and Forecasts 2022 โ 2032โ. The report provides a detailed analysis of ...See details»
Biotest AG: Grifols acquires majority of voting rights in Biotest
Source from : Yahoo Finance - 2 days ago
On 12 April 2022, Biotest AG notified that the last outstanding condition for the takeover offer of Grifols S.A. had been fulfilled. Today Grifols SA announced that the voluntary takeover offer ...See details»
GigaGen Publishes Research Demonstrating the Potential of its Machine Learning Platform to Improve Antibody Drug Discovery and Development
Source from : Associated Press - 6 days ago
GigaGen Inc., a biotechnology company advancing transformative antibody drugs for immune deficiencies, infectious diseases and checkpoint resistant cancers, and a subsidiary of Grifols, announced ...See details»
Alpha-1 Antitrypsin Deficiency Treatment Market: Strong Product Pipeline is Expected to Give Impetus to Growth, says Fortune Business Insights
Source from : FOX 40 WICZ TV - 13 days ago
In November 2017, Grifols, S.A., received FDA approval for A1AT Genotyping Test for the diagnosis of alpha-1 antitrypsin deficiency serving as an innovative genetic test which will enable precise and ...See details»
Global Blood Testing Market Forecast to 2029 - Featuring Abbott Laboratories, bioMerieux and Grifols Among Others - ResearchAndMarkets.com
Source from : The Register-Herald - 6 days ago
Companies Mentioned Abbott Laboratories Becton, Dickinson and Company bioMerieux SA Bio-Rad Laboratories Cepheid Corporation Danaher (Beckman Coulter) Grifols, S.A. Novartis International ...See details»